Emyria (ASX:EMD) is pleased to announce the Company’s distinguished psychiatry specialist has been granted “Authorised Prescriber” status by the Therapeutic Goods Administration.
This authorisation reflects Emyria’s dedication to pioneering mental health care for the treatment of Post-Traumatic Stress Disorder (PTSD) under strict regulatory, ethical, and safety standards. It signifies a strategic step towards expanding Emyria’s service offerings within the TGA guidelines.
PTSD affects approximately 1 million Australians, and there is a growing need for more effective treatments. Emyria is currently studying MDMA-assisted therapy (MDMA-AT) for PTSD in an ethics-approved clinical trial (EMDMA-001). Experience with the trial has informed a unique delivery model for Emyria’s Authorised Prescriber program.
Dr. Michael Winlo, CEO and MD, stated:
“This authorisation demonstrates Emyria’s commitment to evaluating emerging treatments within the strict regulatory framework set by the TGA.
“Emyria’s expertise and track record in innovative clinical service development and Real-World Data capture uniquely positions us to evaluate new therapeutic options in a safe and responsible way. Achieving Authorised Prescriber status showcases Emyria’s capacity for impactful and responsible growth in the field of mental health treatments.”
